文献速递创伤与烧伤心脑血管急症重症综合管理与镇静镇痛

早期单剂外泌体治疗改善猪创伤性脑损伤与失血性休克7天模型的神经功能结局

Early single-dose exosome treatment improves neurologic outcomes in a 7-day swine model of traumatic brain injury and hemorrhagic shock.
PubMed 文献 · J Trauma Acute Care Surg · 2020-01-01
一句话结论在猪创伤性脑损伤合并失血性休克模型中,休克1小时后单剂外泌体治疗可降低前4天神经严重程度评分、缩小7天脑病灶并抑制炎症与凋亡。

研究在Yorkshire猪中建立严重创伤性脑损伤(8 mm皮层撞击)与失血性休克(估计总血容量40%)模型,休克1小时后随机(每队列n=4)给予乳酸林格液5 mL或乳酸林格液加外泌体(1×10外泌体颗粒),再休克1小时后用生理盐水复苏。外泌体组前4天神经严重程度评分显著更低(p<0.05)、神经恢复更快,7天脑病灶显著更小(p<0.05)。外泌体组炎症标志物(IL-1、IL-6、IL-8、IL-18)显著更低、GM-CSF更高,BAX与NF-κB显著更低(p<0.05),BDNF显著更高(p<0.05)。作者结论认为早期单剂外泌体治疗在7天内减轻神经损伤、缩小脑病灶、抑制炎症与凋亡并促进神经可塑性。

要点

  • 在猪严重TBI(8 mm皮层撞击)合并失血性休克(估计总血容量40%)模型中,休克1小时后单剂外泌体(1×10外泌体颗粒)治疗使前4天神经严重程度评分显著更低(p<0.05)。
  • 外泌体组7天脑病灶尺寸显著小于对照组(p<0.05)。
  • 外泌体组炎症标志物IL-1、IL-6、IL-8、IL-18显著更低,GM-CSF显著更高(p<0.05)。
  • 外泌体组BAX与NF-κB显著更低、BDNF显著更高(p<0.05),提示抑制凋亡与促进神经可塑性。
  • 该结果为大型动物7天存活模型,每队列n=4,作者结论为早期单剂外泌体治疗 attenuates 神经损伤,尚非临床推荐。

适用人群与场景

  • Yorkshire猪,遭受严重创伤性脑损伤(8 mm皮层撞击)与失血性休克(估计总血容量40%),休克1小时后随机分组,再休克1小时后复苏,观察至7天。

处置流程与药物剂量

  • 休克1小时后随机给予乳酸林格液5 mL(对照)或乳酸林格液加外泌体(1×10外泌体颗粒)单剂治疗。
  • 再休克1小时后用生理盐水复苏。
  • 每日比较神经严重程度评分,7天后比较脑病灶大小、炎症标志物及NF-κB、BAX、BDNF水平。

研究设计与关键结果

  • 研究类型:大型动物(猪)7天存活模型,随机分组,每队列n=4。
  • 干预与对照:休克1小时后单剂外泌体(1×10外泌体颗粒)加乳酸林格液 vs 乳酸林格液5 mL。
  • 主要终点:外泌体组前4天神经严重程度评分显著更低(p<0.05),神经恢复更快。
  • 7天脑病灶:外泌体组显著更小(p<0.05)。
  • 炎症标志物:外泌体组IL-1、IL-6、IL-8、IL-18显著更低,GM-CSF显著更高(p<0.05)。
  • 分子标志物:外泌体组BAX与NF-κB显著更低(p<0.05),BDNF显著更高(p<0.05)。

证据类型、等级与局限

  • 证据类型:大型动物(猪)随机对照实验,7天存活模型。
  • 局限:每队列n=4,样本量小;作者结论基于动物模型,原文未报告其他局限性。

对床旁实践的改变

  • 作者认为,在TBI与HS大型动物模型中,早期单剂外泌体治疗可减轻神经损伤、缩小脑病灶、抑制炎症与凋亡并促进神经可塑性;该结果尚不能直接转化为急诊/ICU临床推荐。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Early single-dose treatment with human mesenchymal stem cell-derived exosomes promotes neuroprotection and promotes blood-brain barrier integrity in models of traumatic brain injury (TBI) and hemorrhagic shock (HS) in swine. The impact of an early single dose of exosomes on late survival (7 days), however, remains unknown. We sought to evaluate the impact of early single-dose exosome treatment on neurologic outcomes, brain lesion size, inflammatory cytokines, apoptotic markers, and mediators of neural plasticity in a 7-day survival model.

METHODS: Yorkshire swine were subjected to a severe TBI (8-mm cortical impact) and HS (40% estimated total blood volume). After 1 hour of shock, animals were randomized (n = 4/cohort) to receive either lactated Ringer's (5 mL) or lactated Ringer's with exosomes (1 × 10 exosome particles). After an additional hour of shock, animals were resuscitated with normal saline. Daily neurologic severity scores were compared. At 7 days following injury, lesion size, inflammatory markers, and mediators of inflammation (NF-κB), apoptosis (BAX), and neural plasticity (brain-derived neurotrophic factor) in brain tissue were compared between groups.

RESULTS: Exosome-treated animals had significantly lower neurologic severity scores (first 4 days; p < 0.05) and faster neurologic recovery. At 7 days, exosome-treated animals had significantly smaller (p < 0.05) brain lesion sizes. Exosome-treated animals also had significantly lower levels of inflammatory markers (interleukin [IL]-1, IL-6, IL-8, and IL-18) and higher granulocyte-macrophage colony-stimulating factor levels compared with the control animals, indicating specific impacts on various cytokines. The BAX and NF-κB levels were significantly lower (p < 0.05) in exosome-treated animals, while brain-derived neurotrophic factor levels were significantly higher (p < 0.05) in the exosome-treated animals.

CONCLUSION: In a large animal model of TBI and HS, early single-dose exosome treatment attenuates neurologic injury, decreases brain lesion size, inhibits inflammation and apoptosis, and promotes neural plasticity over a 7-day period.

来源:J Trauma Acute Care Surg,查看原文。版权归原作者所有。

参考来源

  1. Williams AM, Wu Z, Bhatti UF, et al. Early single-dose exosome treatment improves neurologic outcomes in a 7-day swine model of traumatic brain injury and hemorrhagic shock. J Trauma Acute Care Surg. 2020. PMID: 32218019. doi:10.1097/TA.0000000000002698

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。